Baird reiterated coverage of AptarGroup with a rating of Neutral and set a new price target of $135.00 from $150.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2025 | $200.00 | Outperform | Raymond James |
| 1/6/2025 | $173.00 | Buy → Neutral | BofA Securities |
| 10/14/2024 | $155.00 → $215.00 | Hold → Buy | Jefferies |
| 4/29/2024 | Mkt Perform → Outperform | William Blair | |
| 1/3/2024 | $125.00 → $150.00 | Neutral → Outperform | Robert W. Baird |
| 1/20/2022 | $150.00 → $126.00 | Equal-Weight | Morgan Stanley |
| 12/22/2021 | $162.00 → $156.00 | Overweight | Wells Fargo |
| 12/20/2021 | $148.00 → $145.00 | Buy | Deutsche Bank |
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar
SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack™ platform. The platform was developed by Aptar's drug services company, Nanopharm. If validated, SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals by proving it can accurately predict clinical outcomes – removing a major barrier for pharma companies and regulators and paving the way for wider patient access to medications. This validation would estab
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
SD - APTARGROUP, INC. (0000896622) (Filer)
S-8 - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
Raymond James initiated coverage of AptarGroup with a rating of Outperform and set a new price target of $200.00
BofA Securities downgraded AptarGroup from Buy to Neutral and set a new price target of $173.00
Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter results due to solid operational performance driven by top and bottom line improvements. Results were driven by sales growth in pharma solutions, increased demand for closures technologies and productivity gains across the company. Reported sales increased by 1% and core sales increased by 2% due to a negative currency effect. Aptar reported net income of $101 million for the quarter, a 62% increase from the prior year. In addition, the quarterly results benefited from a lower effective tax rate. This press release features multimedi